Gm-Csf
Lymphoma, Mantle Cell
National Cancer Institute (NCI)Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Lymphoma, Mantle Cell cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Campath National Cancer Institute (NCI) | Phase 2 | CCC |
ly4152199 - iv Eli Lilly and Company | Phase 1 | CC |
Same molecule, other indications
Gm-Csf is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →